Key Points
- Director Richard Peter Marshall bought 12,183 shares of Serina Therapeutics at $1.65 per share, spending about $20,101.95, according to an SEC filing.
- Serina Therapeutics stock was up 4.9% and opened at $1.98 on Friday, near its 50-day moving average of $1.95.
- The biotech company reported a Q1 EPS of -$0.58 and continues to develop treatments for Parkinson’s disease, pain, epilepsy, and other conditions.
Serina Therapeutics, Inc. (NYSEAMERICAN:SER - Get Free Report) Director Richard Peter Marshall bought 12,183 shares of the firm's stock in a transaction that occurred on Tuesday, May 19th. The shares were purchased at an average cost of $1.65 per share, with a total value of $20,101.95. Following the acquisition, the director directly owned 12,183 shares of the company's stock, valued at approximately $20,101.95. This trade represents a ∞ increase in their ownership of the stock. The purchase was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through the SEC website.
Serina Therapeutics Stock Up 4.9%
Serina Therapeutics stock opened at $1.98 on Friday. The company has a debt-to-equity ratio of 0.24, a current ratio of 4.18 and a quick ratio of 4.18. Serina Therapeutics, Inc. has a 52 week low of $1.22 and a 52 week high of $7.92. The firm has a market capitalization of $29.70 million, a P/E ratio of -0.99 and a beta of 1.15. The business's 50-day moving average price is $1.95.
Serina Therapeutics (NYSEAMERICAN:SER - Get Free Report) last released its earnings results on Thursday, May 14th. The company reported ($0.58) EPS for the quarter.
Serina Therapeutics Company Profile
(
Get Free Report)
Serina Therapeutics, Inc, a biotechnology company, develops drugs to treat neurological diseases and pain. Its lead product candidate is SER 252, a POZ conjugate for the treatment of Parkinson's disease. The company also develops SER 227 for long-acting pain relief; SER 214 to treat Parkinson's disease; and SER 228 for the treatment of epilepsy. In addition, it develops POZ technology in lipid nanoparticle delivered ribonucleic acid vaccines for infectious diseases. Serina Therapeutics, Inc was founded in 2006 and is based in Huntsville, Alabama.
Recommended Stories
This instant news alert was generated by narrative science technology and financial data from InsiderTrades.com in order to provide readers with the fastest and most accurate reporting. Please send any questions or comments about this story to [email protected].
